Mirum Pharmaceuticals to Present at SVB Leerink 11th Annual Global Healthcare Conference

Rhea-AI Summary

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) will participate in the SVB Leerink 11th Annual Global Healthcare Conference from February 14-18, 2022. The company is scheduled to present on February 16, 2022, at 4:20 p.m. ET. Mirum is focused on developing treatments for rare diseases, including its approved drug LIVMARLI® for Alagille syndrome. The company also has investigational treatments in clinical trials for various liver diseases, demonstrating its commitment to improving patient outcomes in this field.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will present during the SVB Leerink 11^th Annual Global Healthcare Conference taking place virtually February 14-18, 2022.

Details:
February 16, 2022
4:20 p.m. ET / 1:20 p.m. PT
Presentation link

Visit the Investors and Media section on Mirum’s website for additional information.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older.

Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 study for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b study for patients with biliary atresia. In addition, Mirum has an expanded access program open in Canada, Australia, the UK and several countries in Europe for eligible patients with Alagille syndrome.

Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for maralixibat for the treatment of cholestatic liver disease in patients with Alagille syndrome.

Mirum’s second investigational treatment, volixibat, also an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the OHANA Phase 2b study for pregnant women with intrahepatic cholestasis of pregnancy, VISTAS Phase 2b study for adults with primary sclerosing cholangitis, and the VANTAGE Phase 2b study for primary biliary cholangitis.

Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220209005460/en/

Mirum Contacts:

Media:

Erin Murphy

media@mirumpharma.com

Investors:

Ian Clements, Ph.D.

ir@mirumpharma.com

Sam Martin

Argot Partners

ir@mirumpharma.com

Source: Mirum Pharmaceuticals, Inc.

FAQ

When is Mirum Pharmaceuticals presenting at the SVB Leerink Conference?

Mirum Pharmaceuticals is scheduled to present on February 16, 2022, at 4:20 p.m. ET.

What is LIVMARLI® and what condition does it treat?

LIVMARLI® (maralixibat) is an approved medication by Mirum Pharmaceuticals for treating cholestatic pruritus in patients with Alagille syndrome.

What investigational treatments is Mirum Pharmaceuticals currently developing?

Mirum is developing treatments for various liver diseases, including maralixibat for pediatric liver diseases and volixibat for intrahepatic cholestasis.

Where can investors find more information about Mirum Pharmaceuticals?

Investors can visit the Investors and Media section of Mirum's website for more information.

What is Mirum Pharmaceuticals' stock symbol?

Mirum Pharmaceuticals' stock symbol is MIRM.